MBX Biosciences
Clinical trials sponsored by MBX Biosciences, explained in plain language.
MBX Biosciences
MBX
NASDAQ
Biotech developing peptide therapies for endocrine and metabolic disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New obesity drug MBX 4291 enters first human safety trial Results expected Oct 2026 (estimated)
- New Once-Weekly shot shows promise for Long-Term hypoparathyroidism control Results expected May 2027 (estimated)